April 5, 2016
(Nature) – Public-health experts have applauded drug giant GlaxoSmithKline (GSK) for unveiling new patent policies that could make it easier for people in the world’s poorest countries to access drugs. But they say that other companies will need to follow suit if patients are to see significant improvements in access to medicines — particularly for much-needed cancer drugs. After GSK’s announcement last week, media attention focused on the London-based company’s plan to stop filing for patents in 50 least developed and low-income countries (LDCs and LICs), such as Afghanistan and Zambia.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.